Recent 8-K filings for EVMN

• October 1, 2026, 8:01 AM ET other material materiality 0.80 positive item 7.01item 9.01

  Evommune's EVO301 hits Phase 2a primary endpoint in atopic dermatitis: 55% EASI reduction vs 22% placebo

  Phase 2a trial (n=70; 48 active, 22 placebo) of IV EVO301 5mg/kg at Baseline and Week 4 met its primary endpoint: 55% LS mean EASI reduction at Week 12 vs 22% on placebo (p<0.01).

• September 8, 2026, 6:05 PM ET other material materiality 0.80 negative item 7.01item 8.01item 9.01

  Evommune's EVO756 Phase 2b fails in atopic dermatitis; AD program halted

  Phase 2b trial of EVO756 in 121 adults with moderate-to-severe AD missed primary and secondary endpoints at all doses.

• August 6, 2026, 4:06 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Evommune Q2 net loss $32.2M; EVO756 AD Phase 2b data due Sept 2026

  Net loss of $32.2M for Q2 2026 vs $13.6M in Q2 2025; cash $288M as of June 30, 2026.

• June 29, 2026, 8:32 AM ET other material materiality 0.80 negative item 7.01item 8.01item 9.01

  Evommune EVO756 Phase 2b misses primary endpoint in CSU; development halted for that indication

  Phase 2b trial of EVO756 in 160 CSU patients did not meet primary endpoint of UAS7 change at 12 weeks at any dose.

• May 7, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Evommune reports Q1 net loss $21.7M; EVO756 Phase 2b data due June 2026 in CSU

  Net loss $21.7M in Q1 2026 vs $14.6M prior year; cash, equivalents and investments $307.0M as of March 31, 2026.

• March 5, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Evommune reports Q4/FY2025 net loss $28.3M/$68.9M; positive EVO301 Ph2a data; $125M raise

  Q4 net loss $28.3M; FY net loss $68.9M vs $66.8M prior year. Revenue $13.0M FY (Maruho deal). Cash $216.7M at Dec 31, 2025.

• February 13, 2026, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements ×2◈ Equity Issuances

  Evommune announces $125M private placement of 4.5M shares at $27.88/share

  Gross proceeds ~$125M from sale of 4,494,279 shares at $27.88 per share to institutional investors.

• February 10, 2026, 6:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Evommune reports positive Phase 2a top-line data for EVO301 in atopic dermatitis

  Primary endpoint met: 99.8% of posterior distribution exceeded 8% improvement threshold vs placebo.

• December 11, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026

  Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event other_material

3 positive 3 negative 9 neutral

source · EVMN on sec.gov